5 December 2023 - The Government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates at levels which have damaged the UK’s international standing with global life science companies.

The announcement follows the agreement in mid November of a new Voluntary Scheme for Pricing, Access and Growth (VPAG), a negotiated alternative scheme which companies can opt into over the Statutory Scheme.

Under the new Statutory Scheme, companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% in 2024, 24.0% in 2025 and 26.8% in 2026.

Read ABPI press release